Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BYClinical & translational immunology

From delivery to integration: CRISPR-mediated large insert gene editing in primary human T cells.

  1. 1School of Biological Sciences The University of Auckland Auckland New Zealand.

Abstract

Large insert gene editing in ex vivo, primary human T cells represents an important approach for engineering next-generation cellular immunotherapies. While CRISPR-based editing is well-established for small genetic modifications, large insert knock-in remains a technical bottleneck. This review examines current strategies for achieving efficient, precise and safe integration of large genetic elements. We compare delivery methods for CRISPR components, highlighting electroporation of Cas9 ribonucleoproteins as the most efficient but often cytotoxic approach; emerging alternatives such as cell-penetrating peptides and lipid nanoparticles offer improved cell viability at the expense of editing efficiency. The influence of genomic locus selection, guide RNA design and chromatin context on editing outcomes, as well as the role of homology-directed repair (HDR) template design is evaluated. Various template formats-including linear double- and single-stranded DNA, plasmids, circular single-stranded (css) DNA and recombinant adeno-associated virus (rAAV)-are assessed for their efficiency, toxicity and risk of off-target integration. Where possible, cross-study normalisation is used to enable meaningful comparisons. rAAV templates consistently achieve the highest insertion rates but come with concerns regarding cost, size limitations and insertional mutagenesis, whereas non-viral approaches such as cssDNA templates show promise. Additionally, we review the use of small-molecule modulators to enhance HDR efficiency, noting trade-offs between improved insertion rates and potential genomic instability. Overall, successful large insert editing requires balancing of editing efficiency, cell viability and genomic safety considerations. Continued optimisation of delivery systems, template design and repair pathway modulation will be critical for advancing scalable and clinically viable T-cell therapies.

Related

  1. Comparison of Prime Editing and CRISPR-Cas Mediated HDR in Correcting CFTR-F508del Mutation in Patient iPSC-Derived Airway Basal Cells
    Olga Volodina, Anna Demchenko, Ekaterina Kondrateva +8
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  2. Protocol for eVLP-mediated CRISPR-Cas9 and prime editing in pancreatic cancer cell lines
    Chloe Timmins-Young, Marco Cordani, Elisa Giovannetti +4
    STAR ProtocolsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMCEurope PMC
  3. LNP-mediated CRISPR gene editing of human vascular endothelial cells in 2D and 3D microfluidic cell culture systems
    Amalie Lykke Olsen, Camilla Blunk Vorsø Brandt, Rasmus Karred Larsen +11
    Molecular therapy. Nucleic acidsPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMCEurope PMCPMC
  4. Protocol for non-viral HDR-based CRISPR/Cas9 platform for small custom editing in primary T cells
    Katariina Mamia, Anniken Solveig Matheson Sollano, Vanja Lundberg +9
    Frontiers in Genome EditingPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMCEurope PMC
  5. Generation of lachrymatory factor synthase-suppressed onion (Allium cepa L.) by Agrobacterium-mediated gene transfer for CRISPR/Cas9 genome editing
    Shoya Tamaru, Shinsuke Imai, Satoshi Watanabe +4
    Frontiers in plant sciencePeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCCrossref
BibTeX
@article{buttle2026from,
  title = {{From delivery to integration: CRISPR-mediated large insert gene editing in primary human T cells.}},
  author = {Ben Buttle and Daniel Verdon and Hilary M Sheppard},
  journal = {Clinical \& translational immunology},
  year = {2026},
  month = oct,
  doi = {10.1002/cti2.70124},
  url = {https://europepmc.org/article/MED/42898134},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - From delivery to integration: CRISPR-mediated large insert gene editing in primary human T cells.
AU  - Ben Buttle
AU  - Daniel Verdon
AU  - Hilary M Sheppard
PY  - 2026
DA  - 2026/10/18
JO  - Clinical & translational immunology
DO  - 10.1002/cti2.70124
UR  - https://europepmc.org/article/MED/42898134
AB  - Large insert gene editing in ex vivo, primary human T cells represents an important approach for engineering next-generation cellular immunotherapies. While CRISPR-based editing is well-established for small genetic modifications, large insert knock-in remains a technical bottleneck. This review examines current strategies for achieving efficient, precise and safe integration of large genetic elements. We compare delivery methods for CRISPR components, highlighting electroporation of Cas9 ribonucleoproteins as the most efficient but often cytotoxic approach; emerging alternatives such as cell-penetrating peptides and lipid nanoparticles offer improved cell viability at the expense of editing efficiency. The influence of genomic locus selection, guide RNA design and chromatin context on editing outcomes, as well as the role of homology-directed repair (HDR) template design is evaluated. Various template formats-including linear double- and single-stranded DNA, plasmids, circular single-stranded (css) DNA and recombinant adeno-associated virus (rAAV)-are assessed for their efficiency, toxicity and risk of off-target integration. Where possible, cross-study normalisation is used to enable meaningful comparisons. rAAV templates consistently achieve the highest insertion rates but come with concerns regarding cost, size limitations and insertional mutagenesis, whereas non-viral approaches such as cssDNA templates show promise. Additionally, we review the use of small-molecule modulators to enhance HDR efficiency, noting trade-offs between improved insertion rates and potential genomic instability. Overall, successful large insert editing requires balancing of editing efficiency, cell viability and genomic safety considerations. Continued optimisation of delivery systems, template design and repair pathway modulation will be critical for advancing scalable and clinically viable T-cell therapies.
SN  - 2050-0068
ER  -